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Abstract
Over the last years, there has been great progress in the treatment of multiple myeloma with many new agents and
combinations having been approved and being now routinely incorporated into treatment strategies. As a result,
patients are experiencing benefits in terms of survival and better tolerance. However, the multitude of treatment
options also presents a challenge to select the best options tailored to the specific patient situation. Lenalidomide is
increasingly being used as part of frontline therapy in newly diagnosed multiple myeloma. This agent is typically
administered until disease progression. It is currently unclear, how to best manage patients, who relapse while
receiving lenalidomide as part of their frontline treatment. We conducted a review to summarize the available
evidence in this setting. Our summary shows that there are very few data from current trials testing new combinations
based on carfilzomib, pomalidomide, or daratumumab that address this specific patient population. Our review is
aimed to summarize the available evidence to assist treatment decision making and to raise awareness of this lack of
data to encourage further analyses and the incorporation of sequencing questions in future trial designs.
Introduction
The treatment of multiple myeloma (MM) has changed
dramatically in the past decade with the introduction of
new drugs into therapeutic strategies, both in the frontline
and in the relapse settings. These drugs have been
incorporated into national and international clinical
guidelines, and have transformed our approach to the
treatment of patients with MM1,2.
With the availability of at least 6 different classes of
approved agents, i.e., alkylators, steroids, proteasome
inhibitors (PIs), immunomodulatory agents (IMiDs), his-
tone deacetylase inhibitors (DACIs) and monoclonal
antibodies (MoAbs) that can be combined in doublet,
triplet or even quadruplet regimens, and used together
with or without high-dose therapy and autologous stem
cell transplantation (ASCT), or in some cases as
continuous treatment, the choice of the optimal strategy
at diagnosis and at relapse represents a challenge for
physicians. Also, problematic is the lack of trials addres-
sing important questions, such as the integration of the
first salvage regimen into the assessment of front-line
therapies in order to define optimal sequencing strategies
and to evaluate progression-free survival 2 (PFS2) as an
important end point in homogeneous patient populations.
Furthermore, there is a substantial lack of pre-planned
large subgroup analyses in most of the recently conducted
trials, which led to the approval of various triplet com-
binations at relapse, concerning issues, such as treatment
of refractory disease versus treatment of relapse occurring
after a treatment-free interval, biochemical versus symp-
tomatic relapse, relapse after 1 prior line versus more
advanced disease, high-risk versus standard risk cytoge-
netics, etc3.
At the time of the first relapse, the treatment choice is
influenced by many patient- and disease-related factors,
such as age, cytogenetics, pre-existing toxicities,
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aggressiveness of the relapse, but mostly by the type of
frontline treatment and the response to the previous
therapy4. Since frontline lenalidomide given until pro-
gression is becoming one of the preferred options to treat
patients with MM1,2, it is important to carefully evaluate
salvage regimens that can be proposed at the time of first
progression on lenalidomide. The aim of this manuscript
is to review current available data for the treatment of
patients progressing on lenalidomide provided as first-line
therapy.
Lenalidomide use as frontline therapy and lenalidomide-
refractoriness
Lenalidomide is increasingly being used as part of
frontline therapy in newly diagnosed MM (NDMM). In
patients treated with upfront ASCT, lenalidomide single
agent at low dose is approved as maintenance therapy
until progression5. In a meta-analysis of 3 randomized
clinical trials using primary-source patient-level data
comparing lenalidomide maintenance versus placebo or
observation, a significant benefit in PFS and overall
survival (OS) were demonstrated with lenalidomide
maintenance after ASCT5. In patients with previously
untreated NDMM, who are not eligible for ASCT,
lenalidomide is also approved in combination with low-
dose dexamethasone (Rd) until disease progression,
based on the results of the randomized FIRST study6. In
the final analysis of this trial, treatment with continuous
Rd significantly improved survival outcomes versus
melphalan-prednisone-thalidomide (MPT), supporting
continuous Rd as a standard of care for patients with
transplant-ineligible NDMM7. In addition, in the pro-
spective SWOG0777 trial, which enrolled patients with
NDMM, who were not intended to undergo immediate
ASCT, Rd was compared to Rd plus bortezomib (VRd)8.
The addition of bortezomib resulted in significantly
improved PFS and OS. Upon completion of induction,
all patients received ongoing maintenance with Rd until
progression. The regimen of VRd followed by Rd until
progression is now also recommended by several
guidelines as upfront therapy for transplant ineligible
patients1,2.
Overall, at the present time, a high proportion of
patients with NDMM receive frontline lenalidomide
until progression, either as single-agent at low dose (10
or 15 mg/day) or at the full dose in combination with
low-dose weekly dexamethasone, meaning that their
disease will progress while on therapy. However, in this
setting, there is no consensus regarding the definition of
lenalidomide-refractoriness. While in some cases, dis-
ease progression will be characterized by a symptomatic
relapse with lytic lesions or other symptoms of end-
organ damage, in other cases, patients will experience a
biochemical relapse only as defined by the IMWG
criteria, with an increase of 25% or more in monoclonal
protein, with an absolute increase of at least 0.5 g/dL,
without symptoms of end-organ damage. The first
group of patients will require the immediate initiation
of an alternative therapy. For the second group of
patients, with a slow rise in the paraprotein level, some
investigators consider that increasing the dose of
lenalidomide from 10–15 mg/day to 25 mg/day and
adding dexamethasone before the occurrence of
symptoms may be effective, at least in standard-risk
patients when relapse occurs during low-dose lenali-
domide maintenance. In fact, no clear data are available
supporting this approach. Among the three trials
included in the meta-analysis that supports the use of
lenalidomide maintenance9–11, salvage therapies fol-
lowing progression on lenalidomide are listed in two of
them10,11, but the outcome of patients treated with an
increased dose of lenalidomide and the addition of
dexamethasone is unknown. These data are also lacking
in the recent Myeloma XI trial, which showed PFS and
OS benefits with lenalidomide maintenance in trans-
plant eligible patients12. Consequently, the majority of
experts consider that salvage therapy consisting of full-
dose lenalidomide plus dexamethasone for patients
progressing on low-dose lenalidomide maintenance is
insufficient, and these patients are often considered
lenalidomide-refractory. These patients were also
rightly excluded from recent randomized phase 3 trials
testing Rd vs Rd plus a third agent (either a PI, [car-
filzomib13, KRd, or ixazomib14, IRd] or a mAb, [elotu-
zumab15, Elo-Rd, or daratumumab16, DRd]). The exact
role of lenalidomide-based triplet combinations in
patients refractory to lenalidomide is unknown, how-
ever, most likely they are suboptimal, and these regi-
mens are therefore rarely used in this setting. The only
study available showing that the addition of a third
agent to lenalidomide and steroids may rescue
lenalidomide-refractory disease is a phase 1/2 trial
reported by the HOVON group17. In 67 patients
(median three prior lines of therapy), Nijhof et al.
showed that the addition of continuous low-dose oral
cyclophosphamide (50 mg/d) to 25 mg lenalidomide
and prednisone (REP regimen) induced a 67% response
rate, with a median PFS and OS of 12.1 and 29 months,
respectively, in lenalidomide-refractory patients (Table
1)17. Interestingly, the majority of lenalidomide-
refractory cases enrolled in the study had progressed
while receiving lenalidomide at 25 mg plus dex-
amethasone. Unfortunately, data for patients progres-
sing on frontline lenalidomide are not reported.
Nevertheless, these remarkable results, which show that
low-dose metronomic oral cyclophosphamide may
revert lenalidomide resistance, needs further
evaluation.
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Outcomes of patients progressing on frontline
lenalidomide therapy: data from phase 3 trials
(Table 1) For a patient progressing on R(d) as frontline
therapy, the logical approach is a switch in the class of
agent, from an IMiD to a PI. Bortezomib-dexamethasone
(Vd) was the first combination used in this setting,
resulting in a PFS ranging from 8 to 10 months18.
Cyclophosphamide may also be added (VCd) to increase
the response rate, but no prospective comparison of Vd
versus VCd in relapse is available. The toxicity of Vd is
well-known, and despite the subcutaneous or weekly
administration of bortezomib, peripheral neuropathy
remains the most important side-effect of this combina-
tion. Several phase 3 trials have evaluated PI-based
combinations using Vd as control arm in RRMM and
although it would have been desirable to know the efficacy
of these combinations in lenalidomide-refractory patients,
the reality is that only few truly lenalidomide-refractory
patients were included. Four trials may be discussed in
this setting: First, the phase 3 randomized ENDEAVOR
study prospectively compared Vd versus carfilzomib-
dexamethasone (Kd) until progression in the relapse set-
ting in patients with 1 to 3 prior lines of therapy19,20. This
study, a head-to-head comparison of two PIs, demon-
strated that both PFS (median 18.7 months vs 9.4)19 and
OS (median 47.6 vs 40)20 were superior with Kd across
the whole group of patients. In this trial, the number of
patients refractory to lenalidomide regardless of the
number of prior lines of therapy was actually small, 51 in
the Kd arm and 45 in the Vd arm, and the exact number
of patients progressing on frontline lenalidomide is
unknown21. The median PFS for the group of
lenalidomide-refractory patients was rather short, 8.6 and
6.6 months with Kd and Vd, respectively21. These findings
suggest that lenalidomide-refractory patients may not
benefit as much from Kd as patients who respond well to
prior lenalidomide (although in both cases, outcomes
were better for Kd than for Vd). No OS data are available
for lenalidomide-refractory patients treated with either
combination. Of note, the schedule of Kd is more
demanding than that of Vd, with intravenous adminis-
tration of carfilzomib at the dose of 56 mg/m2 on days 1,
2, 8, 9, 15, and 16 in 28-day cycles until progression. The
safety profile is also different from that of Vd, with fewer
cases of PN, but higher rates of hypertension, dyspnea,
cardiac failure and acute renal failure instead. Never-
theless, the rates of treatment discontinuation due to
adverse events were identical in the two arms of the study.
Recently, Vd was compared to Vd plus daratumumab
(DVd) in patients with relapsed MM who had received at
least one prior line of therapy (CASTOR trial)22. The
triplet combination was associated with a significant PFS
improvement (median not reached versus 7.2 months,
Hazard Ratio, HR, 0.39)22, which was confirmed in an
updated analysis, in which, after a median follow-up of
19.4 months, the median PFS for DVd was 16.7 versus
Table 1 Sub-analysis of patients with lenalidomide-refractory disease in phase 3 and 1b/2 trials: number of enrolled
patients and PFS outcomes
Phase 3 trials
Endeavor21 Castor23 Optimissm28
Kd Vd DVd Vd PVd Vd
Len-refractory to any prior line, n= 51 45 60 81 120 118
Median PFS months 8.6 6.6 7.8 4.9 9.5 5.6
Len-refractory to 1 prior line, n= UK UK UK UK 64 65
Median PFS months UK UK UK UK 17.8 9.5
Phase 1b/2 trials
Trial REP17 MMY100124 MMY100124 MM01432 EMN36
Regimen Len-Cy-Pred DKd DPd DPd KPd
Len-refractory to any prior line, n= 67 51 92 84 60
Median PFS months 12.1 12-month: 65% 10.1 9-month: 86% 18
Len-refractory to 1 prior line, n= UK 6 UK UK 60
Median PFS months UK UK UK UK 18
Kd Carfilzomib-dexamethasone, Vd bortezomib-dexamethasone, DVd daratumumab- bortezomib-dexamethasone, PVd pomalidomide-bortezomib-dexamethasone,
Len-Cy-Pred lenalidomide-cyclophosphamide-dexamethasone, D-Kd daratumumab-carfilzomib-dexamethasone, D-Pd daratumumab-pomalidomide-dexamethasone,
Isa-Pd isatuximab-pomalidomide-dexamethasone, KPd carfilzomib-pomalidomide-dexamethasone, Len-refractory lenalidomide-refractory, PFS progression-free
survival, UK unknown
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7.1 months for Vd alone, HR 0.3123. As in the ENDEA-
VOR study, the number of patients progressing on
frontline lenalidomide is unknown. The only information
available is based on a sub-analysis, showing that patients
refractory to lenalidomide, regardless of the number of
prior lines of therapy, (DVd, n= 60; Vd, n= 81) also
achieved a significant PFS benefit with DVd versus Vd,
with medians of 7.8 versus 4.9 months, respectively, not
very different from the data reported in the ENDEAVOR
study for a similar subgroup of patients24. Overall survival
data for this subgroup of patients are not available to date.
Importantly, the safety profile of the triplet combination is
acceptable, and daratumumab was not found to add any
significant toxicity to the Vd combination.
The phase 3 Panorama 1 study, comparing Vd vs Vd+
panobinostat, enrolled a subgroup of patients progressing
on lenalidomide as frontline therapy, but the number of
patients in this setting was very small and prior treatment
with lenalidomide was not a stratification factor25. Over-
all, the study showed that the combination of Vd+
panobinostat improved PFS by four months, but did not
result in an OS benefit26. The toxicity observed in the
panobinostat arm of the trial, especially the high fre-
quency of grade 3–4 gastro-intestinal adverse events,
fatigue and thrombocytopenia, does not argue in favor of
the use of this triplet combination in lenalidomide-
refractory patients.
Most recently, the phase 3 OPTIMISMM trial was con-
ducted in patients with relapsed and/or refractory MM
(median two prior lines of treatment). In this trial, the
combination of pomalidomide, bortezomib and dex-
amethasone (PVd) demonstrated a significantly improved
PFS (11.20 vs 7.10 months, HR 0.61) and a manageable
safety profile compared to Vd27. This trial is different to
those reviewed previously because it is the first and only
phase 3 randomized trial, in which all patients had pre-
viously received lenalidomide. Moreover, 70% of patients
were lenalidomide-refractory and among these, a significant
number had received lenalidomide as first-line therapy and
received either PVd (57.7%) or Vd (56.5%) as first rescue
treatment. In an exploratory analysis, which compared the
efficacy and safety of PVd vs Vd in patients with
lenalidomide-refractory and lenalidomide-non refractory
disease treated after one prior line of therapy, PVd was
shown to reduce the risk of progression or death regardless
of lenalidomide-refractoriness28. The median PFS was
17.84 months in the PVd arm (n= 64) vs 9.49 in the Vd
arm (n= 65) for patients with lenalidomide-refractory dis-
ease after one prior line of treatment. This regimen, effec-
tive and tolerable in patients, for whom lenalidomide is no
longer a treatment option, is not yet approved, but repre-
sents an interesting option at first relapse following lenali-
domide, although OS data are lacking due to the relatively
short follow-up (16.4 months)28.
Overall, the analyses of these four phase 3 trials show
that few patients refractory to frontline lenalidomide
therapy have been evaluated to date. This is not unex-
pected for PANORAMA-1, CASTOR and ENDEAVOR,
which were designed before frontline lenalidomide given
until progression became a frequently used treatment
strategy, especially in Europe. The OPTIMISMM study,
the last to be reported, which was intended to include
patients previously exposed to lenalidomide, is closer to
the real life setting and PVd therefore represents a rea-
listic and effective combination. DVd and Kd, approved in
RRMM, are also feasible, although their efficacy in
patients progressing on frontline lenalidomide remains to
be clarified. Vd-panobinostat would represent the last
choice considering both efficacy and safety.
Outcomes of patients progressing on frontline
lenalidomide therapy: data from phase 1b/2 trials
As previously stated, there is a lack of phase 3 trial data
in RRMM that can be used to make treatment decisions in
patients progressing on frontline lenalidomide therapy,
mainly because those trials were conducted before lena-
lidomide became widely used as continuous therapy in
frontline (Table 1). However, there is some data regarding
this particular group of patients from phase 2 trials, which
evaluated new combinations based on PIs and/or poma-
lidomide +/− MoAbs. Major limitations are the small
number of patients, as well as the short follow-up, and
lack of OS data.
Jakubowiak et al. reported data of a phase 2 randomized
trial comparing Vd versus Vd+ elotuzumab in 152
patients with RRMM showing a PFS benefit of the triplet
combination in the intent-to-treat population (9.7 vs.
6.9 months)29. Sixty-six percent of the patients were
treated at the time of the first relapse, but the number of
cases progressing on lenalidomide is not reported, and a
subgroup analysis of patients previously treated with
IMiDs showed no PFS benefit of the addition of elotu-
zumab to Vd (HR: 0.87, 95% CI: 0.56–1.34)29.
The CHAMPION-1 trial evaluated the more convenient
weekly administration of carfilzomib in combination with
dexamethasone in RRMM30. In the phase 2 portion of
the study, 31 / 89 patients (35%) treated at the dose
of 70 mg/m2 carfilzomib were refractory to lenalidomide
(not all of them at first relapse), and the response rate was
71%, very similar to the 74% ORR observed for the whole
group of patients. The median PFS was 12.6 months for
104 patients treated at the maximum tolerated dose of
70 mg/m2 (phase 1 and 2), but the median PFS for
patients refractory to frontline lenalidomide was not
reported. A recent analysis was conducted on all patients,
who had progressed on frontline lenalidomide therapy
and were treated with Kd in both the ENDEAVOR (bi-
weekly carfilzomib) and CHAMPION-1 (weekly
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carfilzomib) trials. The number was small (only 32
patients were identified overall), and the promising
median PFS of 15.6 months requires confirmation in
future studies31.
Carfilzomib and dexamethasone have been combined
with daratumumab (D-Kd) in the phase 1b
MMY1001 study24. Carfilzomib was used weekly at
70 mg/m2 plus low-dose dexamethasone, and the dose of
daratumumab was 16 mg/kg QW on cycles 1–2, Q2W on
cycles 3–6, and Q4W thereafter until progression. The
trial included 85 patients, with 51 of them (59%) having
lenalidomide-refractory disease (median two prior lines of
therapy). The ORR was 79% for lenalidomide-refractory
patients, and the 12-month PFS rate was 65% in this
cohort (median follow-up 16.6 months)24, while OS data
are not yet available. In the group of lenalidomide-
refractory patients, only six were refractory to frontline
lenalidomide. Therefore, the promising PFS achieved with
this D-Kd regimen needs to be confirmed in our popu-
lation of interest.
In the same MMY1001 trial, another arm tested the
combination of pomalidomide-dexamethasone plus dar-
atumumab (D-Pd)24. Ninety-two patients out of 102
enrolled into this arm were lenalidomide-refractory. The
ORR for the whole group of patients was 66%, and the
median PFS was 10.1 months after a median follow-up of
28.1 months. However, the number of patients progressing
on frontline lenalidomide therapy included in this arm is
unknown. The same combination, D-Pd, has been tested
in 112 patients progressing after lenalidomide-based
therapy (median two prior lines of therapy), of whom 84
(75.0%) were refractory to lenalidomide, in another phase
2 MM-014 trial conducted in North America (median
follow-up 8.2 months)32. The ORR (primary end-point)
was 75% in lenalidomide-refractory patients, and the 9-
month PFS rate was 86.3% (range 76.5%-92.2%), while the
median PFS was not estimable32. Here again, data focusing
on patients with disease that is refractory to frontline
lenalidomide are not available. Pomalidomide-
dexamethasone has also been combined with MOR202,
another MoAb targeting CD38, in a phase 1/2a study
involving 21 patients (median three prior lines of therapy),
with a median PFS of 17.5 months. However, there were
only very few patients, who were treated with this com-
bination for first relapse after frontline lenalidomide, and
results in this subgroup of cases are not available33.
There are other pomalidomide-dexamethasone-based
combinations that have been evaluated in populations
that included patients with lenalidomide-refractory dis-
ease, but patients, who had received just one prior line of
therapy, were not allowed to be included. These studies
can therefore not be used to answer the question about
the optimal combinations to rescue patients progressing
on frontline lenalidomide therapy. Nevertheless, we
briefly describe their results here because they will
potentially be tested in the future in the population that is
the subject of this manuscript. Pomalidomide-
dexamethasose plus isatuximab, a third MoAb targeting
CD38, has been evaluated in a phase 1b study including
45 patients with RRMM, 37 (82%) of whom were
lenalidomide-refractory and had advanced disease with at
least 2 prior lines of therapy (median 3). The combination
resulted in a promising response rate and PFS (median
17.6 months for the whole group of patients)34. Another
potential combination is pomalidomide-dexamethasone
plus elotuzumab, which was tested in a phase 2 rando-
mized trial versus pomalidomide-dexamethasone in
patients mostly refractory to lenalidomide and PIs.
However, this ELOQUENT-3 study, which showed
improved PFS results in the elotuzumab arm (median
10.3 months) enrolled only patients who had received at
least 2 prior lines of therapy, and no patients progressing
on frontline lenalidomide were included35.
Finally, over the last few years, some trials that are
being planned in the population of patients with newly
diagnosed MM also include designs to evaluate rescue
strategies for these patients. In line with this, pomali-
domide has been combined with twice-weekly 56 mg/m2
carfilzomib and dexamethasone (KPd) in the pro-
spective EMN011/HO114 trial conducted by the Eur-
opean Myeloma Network36. This phase 2 trial was
designed for patients with refractory disease or first
progression after having received therapy as part of the
EMN02 trial, in which patients were randomized to
frontline ASCT versus no frontline ASCT followed by
consolidation and lenalidomide maintenance until pro-
gression. The analysis of the first 60 patients, 57 (95%)
of whom had progressed on lenalidomide maintenance,
was presented at the 2018 meeting of the American
Society of Hematology. After four 28-day cycles of re-
induction with KPd, patients were offered either salvage
ASCT, if they had not received frontline intensive
therapy, or four additional cycles of KPd (8 KPd cycles
overall). Subsequently, patients with stable disease or
better received pomalidomide 4 mg with or without
dexamethasone in 28 days cycles until progression36.
Responses to KPd were quick, with a median time to
best response of two months. The toxicity of KPd was
manageable, and at a median follow-up of 16.3 months,
the median PFS was 18 months, with a better outcome
in patients with standard-risk cytogenetics (HR= 0.27)
and in patients, who had not received frontline ASCT
(n= 25, HR= 0.49).
There are other new agents, which have been tested in
combination with Vd in phase 1b/2 trials in RRMM, such
as Vd+ venetoclax37, or Vd+ selinexor38, but no data are
available in the specific subgroup of patients progressing
on frontline lenalidomide.
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Overall, the analyses of these different phase 2 trials
show that only few patients refractory to frontline
lenalidomide therapy can be evaluated, however, pro-
mising results were achieved with the combination of
carfilzomib or pomalidomide plus a MoAb targeting
CD38, or with the combination of carfilzomib plus
pomalidomide.
Important ongoing phase 3 trials in lenalidomide-
refractory patients
Some of the phase 2 trials discussed above are the basis
for important ongoing phase 3 studies in RRMM that will
help in the identification of the best options for patients
progressing on frontline lenalidomide (Table 2). These
trials are comparing Kd +/− antiCD38 monoclonal
Table 2 Primary end-point, main inclusion criteria and estimated enrollment of ongoing phase 3 trials that include
patients progressing on lenalidomide
CANDOR (NCT03158688):
Objective:
-To compare Kd, and Daratumumab-Kd in terms of PFS in patients with MM who have relapsed after 1 to 3 prior therapies.
Main inclusion criteria:
-Relapsed or progressive MM after last treatment
-Received at least 1, but not more than 3 prior lines of therapy for MM
Estimated enrollment: 466 patients
IKEMA (NCT03275285):
Objective:
-To compare Kd, and Isatuximab-Kd in terms of PFS in patients with MM who have relapsed after 1 to 3 prior therapies.
Main inclusion criteria:
-Patients with MM previously treated with prior 1 to 3 lines
Estimated enrollment: 300 patients
ICARIA (NCT 02990338):
Objective:
-To compare Pom-dex, and Isatuximab-Pom-dex in terms of PFS in patients with RRMM
Main inclusion criteria:
-Patients must have received at least 2 prior lines of anti-myeloma therapy
-Patients must have failed treatment with lenalidomide and a proteasome inhibitor
-Patients must have progressed on or within 60 days after end of previous therapy before study entry, i.e., refractory to the last line of treatment
Estimated enrollment: 300 patients
APPOLLO / EMN14 (NCT 03180736):
Objective:
-To compare Pom-dex, and Daratumumab-Pom-dex in terms of PFS in patients with RRMM
Main inclusion criteria:
-Subjects must have received prior anti-myeloma treatment. The prior treatment must have included both a PI- and lenalidomide-containing regimen. The
subject must have had a response to prior therapy
-Subjects must have documented evidence of PD on or after the last regimen
-Subjects who received only 1 line of prior treatment must have demonstrated PD on or within 60 days of completion of the lenalidomide-containing
regimen
Estimated enrollment: 302 patients
BOSTON (NCT03110562):
Objective:
-To compare Vd, and Vd-Selinexor in terms of PFS in patients with RRMM
Main inclusion criteria
-Patients must have received at least 1 prior anti-MM regimen and no more than 3 prior anti-MM regimens
-Documented evidence of progressive MM on or after their most recent regimen
Estimated enrollment: 364 patients
BELLINI (NCT02755597):
Objective:
-To compare Vd-placebo, and Vd-Venetoclax in terms of PFS in patients with RRMM
Main inclusion criteria
-Participant has documented relapsed or progressive MM on or after any regimen, or refractory to the most recent line of therapy
-Participant must have received prior treatment with at least one, but no more than three prior lines of therapy for MM
Estimated enrollment: 291 patients
Kd carfilzomib-dexamethasone, Pom-dex pomalidomide-dexamethasone, Vd bortezomib-dexamethasone
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antibodies, Pomalidomide-dexamethasone +/− antiCD38
monoclonal antibodies, Vd +/− venetoclax or Vd +/−
selinexor and the first results are expected in 2019.
Nevertheless, the limitation is that not only patients with
disease refractory to frontline lenalidomide are included
and the trials will therefore provide only subgroup
analyses.
Conclusion
The number of patients treated with frontline lenali-
domide that will progress while on therapy is likely to
increase markedly in the coming years. To date, very few
trials have targeted this patient population in order to
define the optimal salvage regimen. The available results
on approved combinations are restricted to a very low
number of patients and show sub-optimal outcomes.
Moreover, no OS data have been published to date.
The most encouraging data are those achieved with the
combinations of PVd or KPd, which are not approved.
The results of ongoing trials using Kd or Pomalidomide-
dexamethasone plus antibodies targeting CD38 are
eagerly awaited.
We should also encourage companies and leading
authors of important trials, in which frontline therapy with
lenalidomide was used either as low-dose single agent
(lenalidomide maintenance after ASCT9–12) or at the dose
of 25mg per day with dexamethasone (for example, con-
tinuous lenalidomide-dexamethasone in the FIRST trial7,
SWOG S07778, or ECOG-E4A0339) to report on the
results of the salvage therapies that patients received at the
time of progression, even if those salvage regimens were
not preplanned in the study. This represents a large
amount of data, that are probably not collected yet, but
that may help to solve the challenging issue of the optimal
rescue therapies after frontline lenalidomide failure.
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